The Food and Drug Administration (FDA) has approved Durolane for the treatment of pain associated with knee osteoarthritis. Durolane is a single-injection, hyaluronic acid (HA) product used for joint lubrication.
In clinical trials, treatment with Durolane effectively relieved pain and restored function for up to six months in patients with knee osteoarthritis.
Bioventus plans to launch Durolane, which has been available in over 25 countries for more than 15 years, in the U.S. in early 2018. The Company has already launched two other products for the treatment of osteoarthritis: three-injection HA Gelsyn-3 and five-injection HA Supartz FX.
For more information visit BioventusGlobal.com.